pharmaphorum1 个月
After disappointing trial, Editas puts lead CRISPR drug on hold
The BRILLIANCE study of EDIT-101 in Leber congenital amaurosis type 10 (LCA10) – an inherited form of blindness – was reported to be the first 'in vivo' CRISPR/Cas9 medicine to be administered ...
MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value
MeiraGTx's financials show $125 million in cash, but additional funding will be needed within the next 12 months. Click for ...
pharmaphorum1 天
First patient dosed in trial of Allergan/Editas’ CRISPR blindness drug
The two companies claim AGN-151587 (EDIT-101) for Leber congenital amaurosis type 10 (LCA10) – an inherited form of blindness – is the first ‘in vivo’ CRISPR medicine to be administered to ...
EurekAlert!3 年
BRILLIANCE Clinical Trial (IMAGE)
The study uses the gene-editing technology CRISPR to repair mutations in the CEP290 gene that cause a rare form of inherited blindness called Leber congenital amaurosis type 10. The trial is ...